Browsing by Subject "irritable bowel syndrome"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Information- and Health-care Seeking Behaviors in Patients With Irritable Bowel Syndrome
    (Elsevier, 2019) Shin, Andrea; Ballou, Sarah; Camilleri, Michael; Xu, Huiping; Lembo, Anthony; Medicine, School of Medicine
    Irritable bowel syndrome (IBS) is a common and clinically heterogeneous gastrointestinal disorder that can be divided into 4 subtypes: IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), IBS with mixed bowel habits, and unclassified IBS. IBS decreases quality of life1 and imposes a substantial economic burden on the healthcare system.2 To develop efficient approaches to address the individual needs of IBS patients while minimizing healthcare resource overutilization, it is important to identify the factors that drive patients to seek care, to clarify the burden associated with distinct IBS subtypes, and to be aware of the resources from which IBS patients seek health-related information. We aimed to compare healthcare and information seeking between individuals with IBS-C and IBS-D. Methods Study Cohort Adults aged 18–100 years were recruited from a national sample to participate in an online consumer survey study between September 14, 2015 and October 21, 2015 to assess healthcare and information seeking. Details of the study design are described elsewhere.3 Statistical Analysis Associations of healthcare and information seeking with IBS subtype were examined by using multivariate logistic regression, negative binomial regression, and the proportional odds model where appropriate adjusting for relevant covariates (age, sex, race/ethnicity, marital status, education level, employment status, and IBS diagnosed by a doctor). Results Healthcare Seeking in Irritable Bowel Syndrome With Constipation and Irritable Bowel Syndrome With Diarrhea Among 3254 participants, 82% (N = 2674) reported speaking to at least 1 healthcare professional about their symptoms. Women with IBS-D were associated with a decreased odds ratio of seeking care from an obstetrician/gynecologist or a pharmacist than women with IBS-C. Among those who saw at least 1 healthcare professional (N = 2674), there were no significant differences in the number of healthcare professionals ever spoken to. However, IBS-D was associated with a decreased number (8% less) of healthcare professionals spoken to in the past 12 months compared with IBS-C. Comparisons of reasons for which participants waited to seek care revealed that IBS-C participants (16.3%) reported that other health conditions took priority more frequently than IBS-D participants (8.0%). Results are summarized in Table 1.
  • Thumbnail Image
    Item
    Long-term effect of moxibustion on irritable bowel syndrome with diarrhea: a randomized clinical trial
    (Sage, 2022-02) Bao, Chunhui; Wu, Luyi; Shi, Yin; Shi, Zheng; Jin, Xiaoming; Shen , Jiacheng; Li , Jing; Hu , Zhihai; Chen, Jianhua; Zeng , Xiaoqing; Zhang, Wei; Ma , Zhe; Weng , Zhijun; Li , Jinmei; Liu , Huirong; Wu , Huangan; Anatomy, Cell Biology and Physiology, School of Medicine
    Background: Moxibustion is increasingly used for treatment of irritable bowel syndrome (IBS). This study investigated the long-term effects of moxibustion for IBS with diarrhea (IBS-D). Methods: Patients with IBS-D were assigned to receive moxibustion or sham moxibustion (52 each, 3× per week, 6 weeks) and were followed up to 24 weeks. The acupoints were bilateral ST25 and ST36, body surface temperatures at acupoints were 43°C ± 1°C and 37°C ± 1°C for the moxibustion and sham groups, respectively. Primary outcome was changes in IBS Adequate Relief (IBS-AR) from baseline to 6 weeks. Secondary outcomes included the following: IBS symptom severity scale (IBS-SSS), Bristol stool form scale (BSS), IBS quality of life (IBS-QOL), and Hospital Anxiety and Depression Scale (HADS). Results: Based on an intention-to-treat analysis, the rate of IBS-AR in the moxibustion group was significantly higher than the sham group at 6 weeks (76.9% versus 42.3%; p < 0.001); the mean decrease of total IBS-BSS score in the moxibustion group was lower than that of the sham group (−116.9 versus −61.5; p < 0.001), both of which maintained throughout the follow-up period. Five specific domains of the IBS-SSS were lower in the moxibustion group than the sham, throughout (p < 0.001). At week 6, the rate of reduction >50 points in IBS-SSS of the treatment group was significantly higher than that of the sham (p < 0.001), which persisted throughout the follow-up period. Similar long-lasting improvements were observed in BSS, stool frequency, and stool urgency (p < 0.001). Improvements of IBS-QOL and HADS were comparable between the groups. Conclusions: Moxibustion treatment benefits the long-term relief of symptoms in IBS-D patients. Trial registration: Clinical trials.gov (NCT02421627). Registered on 20 April 2015.